Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23015094 | 1.00 | ACP1 (0.66) | ACP1SLC2A1 | |
| SCHEMBL23015244 | 0.98 | ACP1 (0.63) | ACP1SLC2A1 | |
| SCHEMBL29636710 | 0.98 | ACP1 (0.63) | ACP1SLC2A1 | |
| Hydrochloric Acid SCHEMBL29636768 | 0.97 | ACP1 (0.62) | ACP1SLC2A1 | |
| SCHEMBL23029674 | 0.92 | ACP1 (0.66) | ACP1SLC2A1 | |
| SCHEMBL23029664 | 0.92 | ACP1 (0.73) | ACP1SLC2A1 | |
| SCHEMBL29636786 | 0.92 | ACP1 (0.73) | ACP1SLC2A1 | |
| SCHEMBL23029619 | 0.91 | ACP1 (0.64) | ACP1SLC2A1 | |
| Hydrochloric Acid SCHEMBL23015218 | 0.91 | ACP1 (0.72) | ACP1SLC2A1 | |
| Hydrochloric Acid SCHEMBL29636824 | 0.91 | ACP1 (0.72) | ACP1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114667145-A | Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders | 拜尔哈文制药股份有限公司 | 2022-06-24 | — | — | CN | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114667145-A | Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders | 拜尔哈文制药股份有限公司 | 2022-06-24 | — | — | CN | disclosed |